Lv21
180 积分 2023-05-10 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
2个月前
已完结
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
3个月前
已完结
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
3个月前
已完结
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer
7个月前
已完结
Longitudinal tissue analysis and correlation of microenvironmental changes with combined immunotherapy and targeted therapy response in metastatic breast cancer
7个月前
已关闭
Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates
8个月前
已完结
皖公网安备34019202002308
